Cwm LLC Acquires 8,465 Shares of Tempus AI, Inc. $TEM

Cwm LLC grew its stake in Tempus AI, Inc. (NASDAQ:TEM) by 4.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 192,194 shares of the company’s stock after purchasing an additional 8,465 shares during the quarter. Cwm LLC’s holdings in Tempus AI were worth $15,512,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Tempus AI in the second quarter valued at about $54,020,000. Geode Capital Management LLC grew its position in shares of Tempus AI by 411.4% during the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock worth $41,264,000 after buying an additional 522,443 shares during the period. KADENSA CAPITAL Ltd bought a new stake in shares of Tempus AI in the 1st quarter valued at about $22,130,000. Marex Group plc acquired a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $26,620,000. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in Tempus AI by 1,747.6% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock worth $26,247,000 after acquiring an additional 390,723 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEM has been the subject of several recent analyst reports. Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Morgan Stanley upped their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. BTIG Research raised their price objective on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Finally, Guggenheim increased their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $84.00.

Insiders Place Their Bets

In other news, Director Jennifer A. Doudna sold 676 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $75.55, for a total transaction of $51,071.80. Following the completion of the transaction, the director directly owned 23,952 shares of the company’s stock, valued at $1,809,573.60. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the sale, the chief financial officer owned 111,250 shares in the company, valued at $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 932,832 shares of company stock worth $71,324,324 in the last 90 days. Company insiders own 26.27% of the company’s stock.

Tempus AI Trading Down 2.4%

TEM opened at $62.70 on Friday. The stock has a market capitalization of $11.15 billion, a P/E ratio of -52.69 and a beta of 4.99. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The firm’s fifty day simple moving average is $75.16 and its 200 day simple moving average is $73.74.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company’s revenue for the quarter was up 84.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) EPS. As a group, research analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.